Abstract
Many advances have been made in the cardiovascular field in the last several decades. Among them is the progress completed to date on the heptapeptide member of the renin-angiotensin system (RAS), angiotensin-(1-7) [Ang-(1-7)]. The peptide's beneficial actions against pathophysiological processes, such as cardiac arrhythmia, heart failure, hypertension, renal disease, preeclampsia, and even cancer are continuously being uncovered. This review encompasses the pharmacology of Ang-(1-7) and expounds upon the peptide's potential as a therapeutic agent against pathological processes both within and outside the cardiovascular continuum.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Angiotensin I / pharmacology*
-
Angiotensin I / physiology
-
Angiotensin I / therapeutic use
-
Animals
-
Antihypertensive Agents / pharmacology*
-
Antihypertensive Agents / therapeutic use
-
Brain / drug effects*
-
Cardiovascular Diseases / drug therapy
-
Heart / drug effects*
-
Humans
-
Kidney / drug effects*
-
Peptide Fragments / pharmacology*
-
Peptide Fragments / physiology
-
Peptide Fragments / therapeutic use
-
Renin-Angiotensin System / drug effects*
-
Renin-Angiotensin System / physiology
Substances
-
Antihypertensive Agents
-
Peptide Fragments
-
Angiotensin I
-
angiotensin I (1-7)